The adjuvant combination of nab-paclitaxel and gemcitabine was not found to improve disease-free survival compared with gemcitabine alone, as confirmed by independent radiological review, in patients with pancreatic cancer.
Original Article: Nab-Paclitaxel Plus Gemcitabine Misses DFS Endpoint in Pancreatic Cancer